AstraZeneca (AZN) PT Set at GBX 6,350 by Credit Suisse Group

Credit Suisse Group set a GBX 6,350 ($82.97) price target on AstraZeneca (LON:AZN) in a research report released on Friday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts have also recently weighed in on AZN. Kepler Capital Markets set a GBX 5,630 ($73.57) price objective on AstraZeneca and gave the stock a buy rating in a research report on Wednesday, August 1st. Liberum Capital reaffirmed a hold rating on shares of AstraZeneca in a research report on Thursday. Shore Capital reaffirmed a hold rating on shares of AstraZeneca in a research report on Tuesday, October 30th. UBS Group set a GBX 5,900 ($77.09) price objective on AstraZeneca and gave the stock a neutral rating in a research report on Thursday. Finally, Cfra set a GBX 6,200 ($81.01) price objective on AstraZeneca and gave the stock a neutral rating in a research report on Friday. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. AstraZeneca currently has an average rating of Hold and an average target price of GBX 5,831.89 ($76.20).

AstraZeneca stock traded up GBX 79 ($1.03) during mid-day trading on Friday, reaching GBX 6,172 ($80.65). 2,861,442 shares of the company were exchanged, compared to its average volume of 2,310,000. AstraZeneca has a twelve month low of GBX 4,260 ($55.66) and a twelve month high of GBX 5,520 ($72.13).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Further Reading: Do You Need a Fiduciary?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit